New pill shows promise against Hard-to-Treat cancers
Disease control
Ongoing
This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…
Phase: PHASE1, PHASE2 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:32 UTC